Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella(Bharat Biotech (India)), Krishna Mohan Vadrevu(Bharat Biotech (India))

The Lancet Infectious Diseases

March 9, 2021

10.1016/s1473-3099(21)00070-0

Cited by 364

Related Papers

Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

|medRxiv|2020|38